A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition
@article{Clarke2003ANF, title={A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition}, author={A. Clarke and F. Brewer and E. Johnson and N. Mallard and F. Hartig and S. Taylor and T. Corn}, journal={Journal of Neural Transmission}, year={2003}, volume={110}, pages={1241-1255} }
Summary. Seven randomised comparative studies were conducted in healthy volunteers to compare the pharmacokinetic and pharmacodynamic profiles of selegiline hydrochloride in a new formulation designed for buccal absorption “Zydis Selegiline” (1.25–10 mg) with conventional selegiline hydrochloride tablets “conventional selegiline tablets” (10 mg). A total of 156 healthy volunteers participated in these studies. Plasma concentrations of selegiline and its primary metabolites, N… CONTINUE READING
Figures, Tables, and Topics from this paper
126 Citations
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
- Psychology, Medicine
- Journal of Neural Transmission
- 2003
- 53
Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain
- Chemistry, Medicine
- Neuropsychopharmacology
- 2015
- 34
- Highly Influenced
- PDF
Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors
- Medicine
- CNS Spectrums
- 2006
- 43
Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
- Medicine
- Drug testing and analysis
- 2019
- 1
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2013
- 12
- Highly Influenced
- PDF
Monamine Oxidase Inhibitors: Current and Emerging Agents for Parkinson Disease
- Medicine
- Clinical neuropharmacology
- 2007
- 60
References
SHOWING 1-10 OF 29 REFERENCES
The influence of metabolism on the MAO-B inhibitory potency of selegiline.
- Chemistry, Medicine
- Current medicinal chemistry
- 2002
- 18
- Highly Influential
Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
- Chemistry, Medicine
- British journal of pharmacology
- 2001
- 285
Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
- Chemistry, Medicine
- The Journal of pharmacology and experimental therapeutics
- 1991
- 77
- Highly Influential
R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
- Chemistry, Medicine
- Journal of neural transmission. Supplementum
- 1987
- 111
Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo
- Chemistry, Medicine
- Journal of neurochemistry
- 1996
- 117
Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl
- Chemistry, Medicine
- Journal of neurochemistry
- 1986
- 244
CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
- Biology, Medicine
- Drug metabolism and disposition: the biological fate of chemicals
- 2001
- 90
- PDF